Skip to main navigation Skip to search Skip to main content

Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes

  • Michela Faggioni
  • , Usman Baber
  • , Jaya Chandrasekhar
  • , Samantha Sartori
  • , William Weintraub
  • , Sunil V Rao
  • , Birgit Vogel
  • , Bimmer Claessen
  • , Annapoorna Kini
  • , Mark Effron
  • , Zhen Ge
  • , Stuart Keller
  • , Craig Strauss
  • , Clayton Snyder
  • , Catalin Toma
  • , Sandra Weiss
  • , Melissa Aquino
  • , Brian Baker
  • , Anthony C DeFranco
  • , Sameer Bansilal
  • Brent Muhlestein, Samir Kapadia, Stuart Pocock, Kanhaiya L Poddar, Timothy D Henry, Roxana Mehran

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: To investigate the use of prasugrel after percutaneous coronary intervention (PCI) in African American (AA) patients presenting with acute coronary syndrome (ACS). BACKGROUND: AA patients are at higher risk for adverse cardiovascular outcomes after PCI and may derive greater benefit from the use of potent antiplatelet therapy. METHODS: Using the multicenter PROMETHEUS observational registry of ACS patients treated with PCI, we grouped patients by self-reported AA or other races. Clinical outcomes at 90-day and 1-year included non-fatal myocardial infarction (MI), major adverse cardiac events (composite of death, MI, stroke, or unplanned revascularization) and major bleeding. RESULTS : The study population included 2,125 (11%) AA and 17,707 (89%) non-AA patients. AA patients were younger, more often female (46% vs. 30%) with a higher prevalence of diabetes mellitus, chronic kidney disease, and prior coronary intervention than non-AA patients. Although AA patients more often presented with troponin (+) ACS, prasugrel use was much less common in AA vs. non-AA (11.9% vs. 21.4%, respectively, P&thinsp;=&thinsp;0.001). In addition, the use of prasugrel increased with the severity of presentation in non-AA but not in AA patients. Multivariable logistic regression showed AA race was an independent predictor of reduced use of prasugrel (0.42 [0.37-0.49], P&thinsp;<&thinsp;0.0001). AA race was independently associated with a significantly higher risk of MI at 90-days and 1 year after PCI. CONCLUSIONS: Despite higher risk clinical presentation and worse 1-year ischemic outcomes, AA race was an independent predictor of lower prasugrel prescription in a contemporary population of ACS patients undergoing PCI.

Keywords

  • African-American
  • acute coronary syndrome
  • clinical outcomes
  • percutaneous coronary intervention
  • prasugrel
  • race

Cite this